ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-OR49

Association of Calcium Channel Blocker Use with Intradialytic Hypotension

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis


  • lefranc Torres, Armida, Brigham and Women's Hospital, Boston, Massachusetts, United States
  • McCausland, Finnian R., Brigham and Women's Hospital, Boston, Massachusetts, United States

Group or Team Name

  • McCausland Lab.

Calcium channel blockers (CCBs) are commonly used as anti-hypertensive agents among patients receiving maintenance hemodialysis (HD). Despite this, little is known regarding the association of CCBs with intra-dialytic hypotension (IDH), an important adverse outcome that is associated with cardiovascular morbidity and mortality.


Using detailed data from kinetic modeling sessions of the Hemodialysis Study, random-effects regression models were fit to assess the association of CCB use versus not with IDH (defined as systolic blood pressure (SBP) <90 mm Hg if pre-HD SBP <160 mm Hg or <100 mm Hg if pre-HD SBP ≥160mm Hg. Models were adjusted for age, sex, race, Kt/V assignment, flux assignment, heart failure, ischemic heart disease, peripheral vascular disease, diabetes mellitus, BUN, ultrafiltration rate, access type (catheter, fistula, graft), pre-HD SBP, and other anti-hypertensive use.


Data was available for 1,838 patients and 64,538 sessions; at baseline 49% of patients were prescribed CCBs. The overall frequency of IDH was 14% with a mean decline from pre- to nadir-SBP of 33 ±15 mmHg. CCB use was associated with a lower adjusted odds of IDH, compared with no use (OR 0.81; 95%CI 0.75, 0.87). The association was most pronounced for those with (OR 0.77; 95%CI 0.69, 0.86) versus without (OR 0.87; 95%CI 0.78, 0.98) a history of HF at baseline (P-interaction=0.05).


Among patients receiving thrice-weekly HD in the Hemodialysis study, CCB use was associated with a lower risk of developing IDH, independent of pre-HD SBP and other anti-hypertensive use. Mechanistic studies are needed to better understand the effects of CCB and other anti-hypertensives on peri-dialytic blood pressure parameters among patients receiving maintenance HD.